176 related articles for article (PubMed ID: 30989798)
1. Successful treatment of a child with idiopathic multicentric Castleman disease associated with hemophagocytic lymphohistiocytosis using tocilizumab.
Wei A; Ma H; Li Z; Zhang L; Zhang R; Wang T
Pediatr Blood Cancer; 2019 Jul; 66(7):e27759. PubMed ID: 30989798
[No Abstract] [Full Text] [Related]
2. Two cases of idiopathic multicentric Castleman disease with nephrotic syndrome treated with tocilizumab.
Furutera N; Fukunaga N; Okita J; Suzuki T; Suenaga Y; Oyama Y; Aoki K; Fukuda A; Nakata T; Uesugi N; Daa T; Hisano S; Shibata H
CEN Case Rep; 2021 Feb; 10(1):35-41. PubMed ID: 32715375
[TBL] [Abstract][Full Text] [Related]
3. Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease?
Abid MB; Peck R; Abid MA; Al-Sakkaf W; Zhang Y; Dunnill GS; Staines K; Sequeiros IM; Lowry L
Hematol Oncol; 2018 Feb; 36(1):320-323. PubMed ID: 28401573
[TBL] [Abstract][Full Text] [Related]
4. Aseptic Meningitis-retention Syndrome Associated with Tocilizumab in a Patient with Idiopathic Multicentric Castleman Disease.
Arakawa A; Iizuka M; Matsuda S; Matsubara E; Yamazaki H; Yoshikawa N; Tanaka H; Yoshizawa T
Intern Med; 2021 Dec; 60(24):3995-3998. PubMed ID: 34219105
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab for focal segmental glomerulosclerosis secondary to multicentric Castleman's disease.
Ebisawa K; Masamoto Y; Tokushige J; Nishi H; Honda K; Hinata M; Toyama K; Nangaku M; Kurokawa M
Ann Hematol; 2019 Aug; 98(8):1995-1997. PubMed ID: 30761408
[No Abstract] [Full Text] [Related]
6. Idiopathic multicentric Castleman disease with arteriolar endotheliopathy and secondary haemophagocytosis.
Campbell CM; Owen DR; Montazeripouragha A; McCormick I; Fajgenbaum DC; Chen LYC
Lancet Haematol; 2022 Jul; 9(7):e546. PubMed ID: 35772433
[No Abstract] [Full Text] [Related]
7. Tocilizumab as an Adjuvant Therapy for Hemophagocytic Lymphohistiocytosis Associated With Visceral Leishmaniasis.
Rios-Fernández R; Callejas-Rubio JL; García-Rodríguez S; Sancho J; Zubiaur M; Ortego-Centeno N
Am J Ther; 2016; 23(5):e1193-6. PubMed ID: 25768375
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 in idiopathic multicentric Castleman's disease after long-term tocilizumab.
Akiyama M; Yasuoka H; Takeuchi T
Ann Hematol; 2017 Dec; 96(12):2117-2119. PubMed ID: 28861599
[No Abstract] [Full Text] [Related]
9. [Evans syndrome complicated with multicentric Castleman disease successfully treated with tocilizumab].
Nakayama H; Kikuchi T; Abe R; Tozawa K; Watanuki S; Shimizu T; Mitsuhashi T; Murata M; Okamoto S; Mori T
Rinsho Ketsueki; 2018; 59(8):997-1001. PubMed ID: 30185717
[TBL] [Abstract][Full Text] [Related]
10. Multicentric Castleman disease presenting as a chylous pleural effusion.
Epstein D; Zohar Y; Ovadya D; Ammouri H; Kremer R; Lavi N; Tzoran I; Andrawas ER; Klein E; Miller A
Pathol Res Pract; 2020 Nov; 216(11):153209. PubMed ID: 32950896
[TBL] [Abstract][Full Text] [Related]
11. Idiopathic Multicentric Castleman Disease with Autoimmune Hemolytic Anemia and Production of Anti-drug Antibody against Tocilizumab.
Tabata S; Higuchi T; Tatsukawa S; Narimatsu K; Takeo H; Matsukuma S; Ito T
Intern Med; 2019 Nov; 58(22):3313-3318. PubMed ID: 31292389
[TBL] [Abstract][Full Text] [Related]
12. A case of Castleman disease with hemophagocytic syndrome derived from HHV8 infection.
Cui X; Wu Y; Jia L; Chang J; Li C; Guo C; Zhang T; Ma Y; Zhang Y
Eur J Med Res; 2021 Oct; 26(1):119. PubMed ID: 34602082
[TBL] [Abstract][Full Text] [Related]
13. Sustained remission of multicentric Castleman disease in children treated with tocilizumab, an anti-interleukin-6 receptor antibody.
Galeotti C; Boucheron A; Guillaume S; Koné-Paut I
Mol Cancer Ther; 2012 Aug; 11(8):1623-6. PubMed ID: 22638145
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Idiopathic Castleman Disease.
van Rhee F; Greenway A; Stone K
Hematol Oncol Clin North Am; 2018 Feb; 32(1):89-106. PubMed ID: 29157622
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab added to conventional therapy reverses both the cytokine profile and CD8+Granzyme+ T-cells/NK cells expansion in refractory hemophagocytic lymphohistiocytosis.
Faguer S; Vergez F; Peres M; Ferrandiz I; Casemayou A; Belliere J; Cointault O; Lavayssiere L; Nogier MB; Prevot G; Huart A; Recher C; Rostaing L
Hematol Oncol; 2016 Mar; 34(1):55-7. PubMed ID: 25312407
[No Abstract] [Full Text] [Related]
16. Cerebral thrombotic event as a rare complication in a young female patient with idiopathic multicentric castleman disease.
Yin H; Zhang L; Pan B; Zhao J; Feng J; Li J
Clin Neurol Neurosurg; 2020 Nov; 198():106246. PubMed ID: 33032104
[No Abstract] [Full Text] [Related]
17. Clinicopathologic characteristics of 342 patients with multicentric Castleman disease in Japan.
Murakami M; Johkoh T; Hayashi S; Ohshima S; Mizuki M; Nakatsuka SI; Tomobe M; Kuroyanagi K; Nakasone A; Nishimoto N
Mod Rheumatol; 2020 Sep; 30(5):843-851. PubMed ID: 31829070
[No Abstract] [Full Text] [Related]
18. Helmet mask and tocilizumab for a patient with hemophagocytic lymphohistiocytosis syndrome and COVID-19: a case report.
Eroglu A; Kartal S; Saral OB
Braz J Anesthesiol; 2021; 71(1):79-83. PubMed ID: 33518836
[TBL] [Abstract][Full Text] [Related]
19. Successful stem cell transplant with antibody-based conditioning for XIAP deficiency with refractory hemophagocytic lymphohistiocytosis.
Worth AJ; Nikolajeva O; Chiesa R; Rao K; Veys P; Amrolia PJ
Blood; 2013 Jun; 121(24):4966-8. PubMed ID: 23766462
[No Abstract] [Full Text] [Related]
20. Idiopathic multicentric Castleman disease preceded by cutaneous plasmacytosis successfully treated by tocilizumab.
Aita T; Hamaguchi S; Shimotani Y; Nakamoto Y
BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33148595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
